These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 15246214)

  • 1. Involvement of the vascular endothelial growth factor receptor-1 in murine hepatocellular carcinoma development.
    Yoshiji H; Kuriyama S; Yoshii J; Ikenaka Y; Noguchi R; Yanase K; Namisaki T; Kitade M; Yamazaki M; Tsujinoue H; Masaki T; Fukui H
    J Hepatol; 2004 Jul; 41(1):97-103. PubMed ID: 15246214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different cascades in the signaling pathway of two vascular endothelial growth factor (VEGF) receptors for the VEGF-mediated murine hepatocellular carcinoma development.
    Yoshiji H; Noguchi R; Kuriyama S; Yoshii J; Ikenaka Y; Yanase K; Namisaki T; Kitade M; Yamazaki M; Uemura M; Fukui H
    Oncol Rep; 2005 May; 13(5):853-7. PubMed ID: 15809749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells.
    Yoshiji H; Kuriyama S; Hicklin DJ; Huber J; Yoshii J; Miyamoto Y; Kawata M; Ikenaka Y; Nakatani T; Tsujinoue H; Fukui H
    Hepatology; 1999 Nov; 30(5):1179-86. PubMed ID: 10534339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Halting the interaction between vascular endothelial growth factor and its receptors attenuates liver carcinogenesis in mice.
    Yoshiji H; Kuriyama S; Yoshii J; Ikenaka Y; Noguchi R; Hicklin DJ; Wu Y; Yanase K; Namisaki T; Kitade M; Yamazaki M; Tsujinoue H; Masaki T; Fukui H
    Hepatology; 2004 Jun; 39(6):1517-24. PubMed ID: 15185292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis.
    Yoshiji H; Kuriyama S; Ways DK; Yoshii J; Miyamoto Y; Kawata M; Ikenaka Y; Tsujinoue H; Nakatani T; Shibuya M; Fukui H
    Cancer Res; 1999 Sep; 59(17):4413-8. PubMed ID: 10485491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regional effects of an antivascular endothelial growth factor receptor monoclonal antibody on receptor phosphorylation and apoptosis in human 253J B-V bladder cancer xenografts.
    Davis DW; Inoue K; Dinney CP; Hicklin DJ; Abbruzzese JL; McConkey DJ
    Cancer Res; 2004 Jul; 64(13):4601-10. PubMed ID: 15231672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma.
    Yoshiji H; Kuriyama S; Yoshii J; Ikenaka Y; Noguchi R; Hicklin DJ; Huber J; Nakatani T; Tsujinoue H; Yanase K; Imazu H; Fukui H
    Hepatology; 2002 Apr; 35(4):834-42. PubMed ID: 11915029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis.
    Yoshiji H; Kuriyama S; Yoshii J; Ikenaka Y; Noguchi R; Hicklin DJ; Wu Y; Yanase K; Namisaki T; Yamazaki M; Tsujinoue H; Imazu H; Masaki T; Fukui H
    Gut; 2003 Sep; 52(9):1347-54. PubMed ID: 12912869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of interferon-beta and the angiotensin-converting enzyme inhibitor, perindopril, attenuates murine hepatocellular carcinoma development and angiogenesis.
    Noguchi R; Yoshiji H; Kuriyama S; Yoshii J; Ikenaka Y; Yanase K; Namisaki T; Kitade M; Yamazaki M; Mitoro A; Tsujinoue H; Imazu H; Masaki T; Fukui H
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):6038-45. PubMed ID: 14676130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of the renin-angiotensin system attenuates vascular endothelial growth factor-mediated tumor development and angiogenesis in murine hepatocellular carcinoma cells.
    Yoshiji H; Yoshii J; Ikenaka Y; Noguchi R; Yanase K; Tsujinoue H; Imazu H; Fukui H
    Int J Oncol; 2002 Jun; 20(6):1227-31. PubMed ID: 12012003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective angiostatic treatment in a murine metastatic and orthotopic hepatoma model.
    Raskopf E; Dzienisowicz C; Hilbert T; Rabe C; Leifeld L; Wernert N; Sauerbruch T; Prieto J; Qian C; Caselmann WH; Schmitz V
    Hepatology; 2005 Jun; 41(6):1233-40. PubMed ID: 15915456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impaired angiogenesis after hindlimb ischemia in type 2 diabetes mellitus: differential regulation of vascular endothelial growth factor receptor 1 and soluble vascular endothelial growth factor receptor 1.
    Hazarika S; Dokun AO; Li Y; Popel AS; Kontos CD; Annex BH
    Circ Res; 2007 Oct; 101(9):948-56. PubMed ID: 17823371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma.
    Huynh H; Ngo VC; Fargnoli J; Ayers M; Soo KC; Koong HN; Thng CH; Ong HS; Chung A; Chow P; Pollock P; Byron S; Tran E
    Clin Cancer Res; 2008 Oct; 14(19):6146-53. PubMed ID: 18829493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth.
    Laakkonen P; Waltari M; Holopainen T; Takahashi T; Pytowski B; Steiner P; Hicklin D; Persaud K; Tonra JR; Witte L; Alitalo K
    Cancer Res; 2007 Jan; 67(2):593-9. PubMed ID: 17234768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth.
    Ebos JM; Lee CR; Bogdanovic E; Alami J; Van Slyke P; Francia G; Xu P; Mutsaers AJ; Dumont DJ; Kerbel RS
    Cancer Res; 2008 Jan; 68(2):521-9. PubMed ID: 18199548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular endothelial growth factor receptor-1 promotes migration and invasion in pancreatic carcinoma cell lines.
    Wey JS; Fan F; Gray MJ; Bauer TW; McCarty MF; Somcio R; Liu W; Evans DB; Wu Y; Hicklin DJ; Ellis LM
    Cancer; 2005 Jul; 104(2):427-38. PubMed ID: 15952180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin.
    Lamszus K; Brockmann MA; Eckerich C; Bohlen P; May C; Mangold U; Fillbrandt R; Westphal M
    Clin Cancer Res; 2005 Jul; 11(13):4934-40. PubMed ID: 16000592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical expression of vascular endothelial growth factor and vascular endothelial growth factor receptor associated with tumor cell proliferation in canine cutaneous squamous cell carcinomas and trichoepitheliomas.
    Al-Dissi AN; Haines DM; Singh B; Kidney BA
    Vet Pathol; 2007 Nov; 44(6):823-30. PubMed ID: 18039895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease.
    Kaushal V; Mukunyadzi P; Dennis RA; Siegel ER; Johnson DE; Kohli M
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):584-93. PubMed ID: 15701844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nicotine induces cyclooxygenase-2 and vascular endothelial growth factor receptor-2 in association with tumor-associated invasion and angiogenesis in gastric cancer.
    Shin VY; Wu WK; Chu KM; Wong HP; Lam EK; Tai EK; Koo MW; Cho CH
    Mol Cancer Res; 2005 Nov; 3(11):607-15. PubMed ID: 16317086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.